uniQure N.V. Ordinary Shares vs ZIM Integrated Shipping Services Ltd — how do they compare? uniQure N.V. Ordinary Shares trades at $20.67 (market cap $1.48B), while ZIM Integrated Shipping Services Ltd trades at $29.84 (market cap $3.67B). The key difference: ZIM Integrated Shipping Services Ltd is far larger — about 2.5× uniQure N.V. Ordinary Shares's market cap, and ZIM Integrated Shipping Services Ltd pays a 20.16% dividend while uniQure N.V. Ordinary Shares pays none. Which is the better fit depends on your goals — on Pluang, investors hold uniQure N.V. Ordinary Shares for 0 Days and ZIM Integrated Shipping Services Ltd for 23 Days on average.
| QURE | ZIM | |
|---|---|---|
Market Cap | $1.48B | $3.67B |
Volume | 2,488,780 | 1,172,596 |
Sector | Health | Industrials |
52-Week High | $70.59 | $30.90 |
52-Week Low | $9.03 | $13.32 |
Typical Hold Time | 0 Days | 23 Days |
Enterprise Value | $728.62M | $7.34B |
Dividend Yield | — | 20.16% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
ZIM trades at $30.43, down 1.52% on the day, with a bullish technical signal from moving averages. The stock is near its 52-week high of $30.96, reflecting strong momentum. Fundamentally, Q2 2026 earnings of $0.53 per share significantly beat expectations, driven by a 9% revenue increase to $1.8 billion, though full-year 2026 guidance indicates margin pressure. The pending $35 per share acquisition offer from Hapag-Lloyd, subject to Israeli government approval, creates a key near-term catalyst.
The investment case balances potential upside from the acquisition against operational risks. If approved, the deal offers immediate premium; if rejected, ZIM's standalone value hinges on sustaining high transpacific freight rates. Analyst sentiment is cautious with no buy ratings, highlighting execution and geopolitical risks. The stock presents a speculative opportunity with binary outcomes centered on the merger decision.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →ZIM is a global container liner shipping company that employs a 'global-niche' strategy, focusing on specific trade lanes where it holds a competitive advantage. Unlike larger, asset-heavy competitors, ZIM operates an agile, charter-intensive fleet, allowing it to rapidly adjust capacity to market demand while prioritizing digitalization and specialized cargo like refrigerated (reefer) goods.
Read more on ZIM →